Multiple sclerosis has long been framed as a disease of the immune system turning against the brain and spinal cord, but a growing body of research points to an unexpected accomplice: the trillions of microbes living in the human gut. A new review published in the Journal of Translational Medicine argues that the intestinal microbiota is not a passive bystander in multiple sclerosis but an active modulator of the immune signaling and barrier failures that drive the disease. More provocatively, the authors, led by researchers at Ain Shams University in Cairo, contend that nearly everything the scientific community believes about the gut–brain axis in multiple sclerosis has been built on Western cohorts, leaving much of the world’s patient population effectively invisible to the emerging field of microbiome-based precision medicine.
The review, authored by Ameera Saeed Alshinnawy, Elham AbdelBadiea Rashwan, Mahmoud Saad Swelam, Mohamed R. Mohamed, and Ahmed A. Sayed, synthesizes global evidence alongside emerging data from underrepresented regions including Egypt, Iran, and India. Their central claim is that dysbiosis — a disturbance in the composition and function of the gut microbial community — is consistently associated with a set of molecular malfunctions that map directly onto multiple sclerosis pathology. Among the most important of these is the impairment of short-chain fatty acid-mediated immunoregulation. Short-chain fatty acids, such as butyrate, propionate, and acetate, are produced when gut bacteria ferment dietary fiber, and they act as chemical messengers that encourage the immune system to stay calm. When the microbes that generate them dwindle, that calming signal weakens.
The mechanistic consequences of that weakened signal are described in detail in the review. With insufficient short-chain fatty acid signaling, the immune balance tips toward proinflammatory Th1 and Th17 responses — the two T-helper cell lineages most closely implicated in attacking the myelin sheaths that insulate nerve fibers in the central nervous system. At the same time, dysbiosis is linked to disruption of both the intestinal epithelial barrier and the blood–brain barrier, the tightly regulated gateways that normally prevent inflammatory cells and molecules from crossing into tissues where they can do harm. A leaky gut, in this model, becomes a training ground for autoreactive immunity, and a compromised blood–brain barrier becomes the door through which that immunity enters the nervous system.
What distinguishes this review from many earlier syntheses is its attention to region-dependent functional signatures. The authors report that microbial disturbances in non-Western populations appear to involve oxidative stress pathways and alterations in neurotransmitter and tryptophan metabolism in ways that differ from the patterns documented in European and North American cohorts. Tryptophan metabolism is particularly significant because it feeds the kynurenine pathway, which generates metabolites capable of influencing both neuroinflammation and neuronal survival. If the microbial handling of tryptophan differs across populations shaped by distinct diets, environments, and genetic backgrounds, then therapeutic strategies calibrated to Western microbiome data may simply not translate for patients elsewhere.
The authors are careful to flag the limits of this emerging evidence. Several of the regional signatures they describe derive from a single pilot-scale cohort and should be regarded as hypothesis-generating until independent studies confirm them. This candor matters, because the field of microbiome research has repeatedly been criticized for overinterpreting small, cross-sectional studies with inconsistent sequencing methodologies. The review explicitly notes that sequencing methodology itself — whether researchers use 16S ribosomal RNA amplicon sequencing, which profiles microbial taxa, or shotgun metagenomics, which can resolve functional genes and strain-level differences — shapes how the data can be interpreted and whether functional claims are justified at all.
On the therapeutic front, the review takes a sober but forward-looking position. Microbiota-derived signals including short-chain fatty acids, lipopolysaccharide, and polysaccharide A are described as modulators of dendritic cell programming, regulatory T-cell differentiation, and neuroinflammatory cascades. Dendritic cells are the sentinels of the immune system, and the microbial context in which they encounter antigens influences whether they prime tolerance or attack. Polysaccharide A, a molecule produced by the commensal bacterium Bacteroides fragilis, has been shown in experimental systems to promote regulatory T cells that suppress inflammation. Lipopolysaccharide, by contrast, is a component of the outer membrane of Gram-negative bacteria that can ignite inflammatory pathways when barrier integrity fails. The therapeutic promise lies in tipping this balance back toward tolerance — but the authors emphasize that current microbiota-targeted interventions remain investigational rather than established disease-modifying therapies for multiple sclerosis.
That caveat is important for patients who may encounter commercial probiotics or drastic dietary regimens marketed as multiple sclerosis remedies. The review evaluates microbiome-targeted strategies — which in the broader literature include probiotics, prebiotics, fecal microbiota transplantation, and defined microbial consortia — and concludes that the field has not yet moved beyond empiric interventions toward personalized, strain-defined biotherapeutics. The distinction between empiric and strain-defined approaches is central to the authors’ argument. Giving every patient the same probiotic assumes a uniform microbial landscape that demonstrably does not exist. A strain-defined biotherapeutic, by contrast, would introduce specific bacterial strains chosen to correct a specific functional deficit identified in a specific patient’s microbiome, much as targeted therapies in oncology are matched to a tumor’s molecular profile.
The review also highlights variables that are routinely underweighted in microbiome studies: sex and regional context. Multiple sclerosis affects women roughly two to three times more often than men, and sex hormones are known to interact with both the immune system and the microbiota, yet many studies fail to stratify their analyses accordingly. Regional context matters even more broadly, encompassing diet, sanitation, antibiotic exposure, parasite history, and genetic ancestry, all of which sculpt the gut ecosystem. The authors argue that these factors influence not only how dysbiosis manifests but also how patients respond to therapeutic interventions, meaning that a therapy validated in Copenhagen or Chicago cannot be assumed to work identically in Cairo, Tehran, or Mumbai without local evidence.
The roadmap the authors propose for regionally equitable precision medicine is arguably the review’s most consequential contribution. They advocate for standardized multi-omics approaches — combining genomics, metagenomics, metabolomics, and immune profiling — so that datasets from different regions can be compared on common analytical ground rather than through incompatible pipelines. They further call for culturally inclusive longitudinal designs, meaning studies that follow patients over time and are designed with awareness of local diets, lifestyles, and healthcare contexts rather than importing Western assumptions wholesale. Longitudinal data are essential because cross-sectional snapshots cannot distinguish whether an observed dysbiosis causes disease, results from it, or merely co-occurs with it.
The stakes of this agenda extend well beyond multiple sclerosis. The gut–brain axis has been implicated in conditions ranging from Parkinson’s disease to depression, and the same Western-centric bias the authors document in multiple sclerosis research likely pervades the wider field. If microbiome science is to deliver on its promise of personalized medicine, it must first establish that its foundational knowledge applies — or fails to apply — across the full diversity of human populations. For the estimated 2.9 million people worldwide living with multiple sclerosis, many of them in regions whose microbiomes have never been systematically studied, the review is both a warning and an invitation: the microbial clues to better treatment may already exist, but only in populations scientists have yet to seriously examine. Turning hypothesis-generating regional signals into validated, strain-defined therapies will require investment, standardization, and a genuine commitment to studying disease in the places where patients actually live.
Subject of Research: Gut microbiota mechanisms and personalized therapeutic strategies in multiple sclerosis
Article Title: Toward regionally equitable precision medicine: microbiota‑associated mechanisms and emerging personalized strategies in multiple sclerosis
Article References: Alshinnawy, A. S., Rashwan, E. A., Swelam, M. S., Mohamed, M. R., & Sayed, A. A. (2026). Toward regionally equitable precision medicine: microbiota‑associated mechanisms and emerging personalized strategies in multiple sclerosis. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08830-7
Image Credits: AI Generated
DOI: 10.1186/s12967-026-08830-7
Keywords: multiple sclerosis, gut microbiota, dysbiosis, short-chain fatty acids, precision medicine, Th17 response, blood-brain barrier, tryptophan metabolism, microbiome sequencing, regional disparities, probiotics, neuroimmunology
News Source: Morgan Morrow. (October 8, 2026). Gut Microbes May Hold the Key to Fairer, Personalized Multiple Sclerosis Care. Scienmag.
